Barclays analyst Gena Wang downgraded Sarepta (SRPT) to Equal Weight from Overweight with a price target of $18, down from $32. The firm highlights the “numerous twist and turns” from both the FDA and company in the past few days following the death of a third patient. Barclays remains “hopeful” for opportunity of Elevidys in ambulatory Duchenne muscular dystrophy patients, but is stepping to the sidelines citing continued regulatory uncertainties.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SRPT:
- Sarepta announces voluntary pause of Elevidys shipments in the U.S.
- Verizon reports Q2 beat, Block to join S&P 500: Morning Buzz
- Sarepta downgraded to Neutral from Buy at UBS
- Target downgraded, Dollar Tree upgraded: Wall Street’s top analyst calls
- Morning Movers: Cleveland-Cliffs rallies after second quarter earnings release